Skip to content

    What is a randomized withdrawal study?

    What is a randomized withdrawal study?

    You may see a weight-care study described as a “randomized withdrawal” trial. The name can sound as though everyone stopped treatment, but that isn't necessarily what happened. Usually, participants first receive a treatment for a period, and eligible participants are then randomly assigned to continue it or switch to a comparison.

    This design can help researchers ask what happens after continuing or stopping treatment in a specific group. It also has limits: the people who reach the randomization stage are a selected group, and the result isn't a personal forecast.

    The first stage: a lead-in

    Imagine a fictional trial in which participants receive a study medicine during an initial period. Researchers monitor their experiences and outcomes. At the end of that period, participants who meet the study's criteria are invited to the next stage.

    The criteria might include completing the lead-in, tolerating treatment or meeting another condition defined in the protocol. Some people who started the trial may not enter the randomized stage. The report should show how many people were included at each step and why others did not continue.

    During an open-label lead-in, participants and researchers may know which treatment is being given. That stage can provide useful information, but it isn't the same comparison as the later randomized period.

    The second stage: random assignment

    Eligible participants are then assigned by chance to different groups. In one common design, one group continues the medicine and another switches to an inactive comparison. The study may keep participants and researchers unaware of the assignment during this stage, depending on its design.

    Researchers compare outcomes after randomization. For example, they may examine how a measure changes over the following year. The relevant starting point for that comparison is the point specified in the study, often the end of the lead-in rather than the day the person first entered the trial.

    This design is used in some weight-management research. In SURMOUNT-4, participants first received tirzepatide for 36 weeks. Of those who enrolled, 670 entered a second stage and were randomly assigned to continue tirzepatide or switch to placebo for 52 weeks. Each trial has its own medication, population, eligibility rules and follow-up. Our look at physical functioning in the STEP trials describes another weight-care study with a continuation-versus-switch stage.

    What the design can answer

    A randomized withdrawal study can estimate a difference between continuing and switching treatment among the people who qualified for randomization, under the conditions of that trial. It can also collect information about side effects and other outcomes during the randomized period.

    For instance, a trial may find that average weight changes differ between the continuation and switch groups. Read the actual numbers, the follow-up period and the uncertainty around the estimate. An average doesn't mean every participant had the same experience.

    The comparison may include other elements, such as lifestyle support in both groups. Knowing what each group received helps you understand what the result is—and isn't—comparing.

    What it doesn't answer by itself

    The randomized group may exclude people who stopped early, couldn't tolerate treatment or didn't meet the lead-in criteria. As a result, the later comparison may not describe what would happen if treatment were offered to everyone who originally entered the study.

    It also doesn't prove that every person who stops a medicine will follow the average pattern observed in the switch group. Individual experiences, health conditions, follow-up care and treatment plans differ.

    Look at the length of follow-up. A study that measures one year after randomization doesn't automatically establish what happens indefinitely. Other studies may address different populations, time periods or ways of stopping treatment.

    Read the participant flow

    The report should show how many people began the lead-in, how many entered the randomized phase and how many completed follow-up. Ask why participants left at each stage and how missing information was handled.

    Also check whether someone who stopped the assigned medicine continued study visits. Stopping treatment and withdrawing from research are different events, and they affect the available information in different ways.

    If the report emphasizes only the result among participants who stayed on treatment, ask what happened to the rest and which analysis represents the study's main question. The details matter for understanding how the result applies to routine care.

    Questions to bring to your clinician

    When a headline cites a withdrawal trial, ask:

    • Who was eligible for the randomized phase?
    • What did the continuation and switch groups receive?
    • From which starting point was the outcome measured?
    • How long were participants followed, and what happened to those who stopped early?
    • What other evidence is relevant to my situation?

    If you're considering a change to a prescribed medicine, talk with your prescriber about your goals, possible effects and follow-up. Don't stop or restart a treatment solely because of a study headline.

    Randomized withdrawal is a useful design for a particular question. Reading both stages makes the result clearer and keeps the conclusion connected to the people actually studied.